The effect of vitamin K2 supplementation on cardiovascular risk markers.

The effect of vitamin K2 supplementation on cardiovascular risk markers. - Vitamin K2 and CVD risk markers.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON35262

Enrollment

Registered

2010-05-21

Start date

2010-06-14

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arteriosclerosis

Interventions

The intervention period is 12 weeks. Intervention group one receives a daily dose of 180 µg vitamin K2 (1 MK-7 capsule of 180 µg + one placebo) Intervention group two receives a daily dose of 360 µg

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Men and women aged >= 40 and = 18.5 and

Exclusion criteria

Exclusion criteria: -Using vitamin K antagonists -Using chronic medication for cardiovascular diseases (beta blockers, bloodthinner medication, rate control medication, cholesterol lowering medication, diuretics, vasodilators) -For women: using menopausal hormone therapy -having a known history with coagulation problems -Smokers -Using vitamin supplements that contain vitamin K, vitamin D or calcium -A high vitamin K2 intake (>= 90 µg/day) -Consuming natto -Vegans -Soy allergy

Design outcomes

Primary

Measure	Time frame
plasma concentrations of conformation-specific MGP (carboxylated and undercarboxylated MGP)	—

Secondary

Measure	Time frame
blood lipid profile, inflammation markers, insulin sensitivity, adipokines and osteocalcin carboxylation	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)